Advances in Pathogenesis and Treatment of Pruritus

Clinics in Liver Disease

Volumn 17, Issue 2, 2013, Pages 319-329

  Bolier, Ruth ^a   Oude Elferink, Ronald P J ^a   Beuers, Ulrich ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Autotaxin; Bile salts; Cholestasis; Itch; Lysophosphatidate; Pruriception

Indexed keywords

AUTOTAXIN; BILE SALT; COLESTYRAMINE; ESTRADIOL; HISTAMINE; LYSOPHOSPHATIDIC ACID; NALOXONE; NALTREXONE; PREGNANE X RECEPTOR; RIFAMPICIN; SERTRALINE; URSODEOXYCHOLIC ACID;

CHOLESTASIS; DIETARY INTAKE; ENVIRONMENTAL FACTOR; HEMODIALYSIS; HEREDITY; HUMAN; LIVER TOXICITY; LIVER TRANSPLANTATION; NERVE CELL EXCITABILITY; NONHUMAN; OBSTRUCTIVE JAUNDICE; PAIN; PATHOGENESIS; PHOTOTHERAPY; PRURITUS; REVIEW; SENSORY NERVE CELL; SEROTONINERGIC NERVE; SKIN; ULTRAVIOLET B RADIATION; WITHDRAWAL SYNDROME;

ANIMALS; ANION EXCHANGE RESINS; ANTIBIOTICS, ANTITUBERCULAR; BILE ACIDS AND SALTS; CHOLESTASIS; CHOLESTYRAMINE RESIN; HUMANS; LYSOPHOSPHOLIPIDS; NARCOTIC ANTAGONISTS; PRURITUS; RECEPTORS, STEROID; RIFAMPIN; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; SIGNAL TRANSDUCTION;

EID: 84875603397     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2012.11.006     Document Type: Review

References (83)

1. Lebovics E., Seif F., Kim D., et al. Pruritus in chronic hepatitis C: association with high serum bile acids, advanced pathology, and bile duct abnormalities. Dig Dis Sci 1997, 42(5):1094-1099.
2. Chia S.C., Bergasa N.V., Kleiner D.E., et al. Pruritus as a presenting symptom of chronic hepatitis C. Dig Dis Sci 1998, 43(10):2177-2183.
3. Neff G.W., O'Brien C.B., Reddy K.R., et al. Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease. Am J Gastroenterol 2002, 97(8):2117-2119.
4. Abraham S.C., Kamath P.S., Eghtesad B., et al. Liver transplantation in precirrhotic biliary tract disease: portal hypertension is frequently associated with nodular regenerative hyperplasia and obliterative portal venopathy. Am J Surg Pathol 2006, 30(11):1454-1461.
5. Kuiper E.M., van Erpecum K.J., Beuers U., et al. The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial. Hepatology 2010, 52(4):1334-1340.
6. Chappell L.C., Gurung V., Seed P.T., et al. Ursodeoxycholic acid versus placebo, and early term delivery versus expectant management, in women with intrahepatic cholestasis of pregnancy: semifactorial randomised clinical trial. BMJ 2012, 344:e3799.
7. Molenaar H.A., Oosting J., Jones E.A. Improved device for measuring scratching activity in patients with pruritus. Med Biol Eng Comput 1998, 36(2):220-224.
8. Inan S., Cowan A. Nalfurafine, a kappa opioid receptor agonist, inhibits scratching behavior secondary to cholestasis induced by chronic ethynylestradiol injections in rats. Pharmacol Biochem Behav 2006, 85(1):39-43.
9. Inagaki N., Igeta K., Shiraishi N., et al. Evaluation and characterization of mouse scratching behavior by a new apparatus, MicroAct. Skin Pharmacol Appl Skin Physiol 2003, 16(3):165-175.
10. Kremer A.E., Martens J.J., Kulik W., et al. Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology 2010, 139(3):1008-1018. 1018.e1.
11. Gingold A.R., Bergasa N.V. The cannabinoid agonist WIN 55, 212-2 increases nociception threshold in cholestatic rats: implications for the treatment of the pruritus of cholestasis. Life Sci 2003, 73(21):2741-2747.
12. Hasanein P., Parviz M., Keshavarz M., et al. Modulation of cholestasis-induced antinociception in rats by two NMDA receptor antagonists: MK-801 and magnesium sulfate. Eur J Pharmacol 2007, 554(2-3):123-127.
13. Kremer A.E., van Dijk R., Leckie P., et al. Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions. Hepatology 2012, 56(4):1391-1400.
14. Gonzalez R., Cruz A., Ferrin G., et al. Cytoprotective properties of rifampicin are related to the regulation of detoxification system and bile acid transporter expression during hepatocellular injury induced by hydrophobic bile acids. J Hepatobiliary Pancreat Sci 2011, 18(5):740-750.
15. Maillette de Buy Wenniger L., Beuers U. Bile salts and cholestasis. Dig Liver Dis 2010, 42(6):409-418.
16. European Association for the Study of the Liver EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009, 51(2):237-267.
17. Jones E.A., Bergasa N.V. Evolving concepts of the pathogenesis and treatment of the pruritus of cholestasis. Can J Gastroenterol 2000, 14(1):33-40.
18. Gittlen S.D., Schulman E.S., Maddrey W.C. Raised histamine concentrations in chronic cholestatic liver disease. Gut 1990, 31(1):96-99.
19. Bergasa N.V. An approach to the management of the pruritus of cholestasis. Clin Liver Dis 2004, 8(1):55-66. vi.
20. Singh V., Bhalla A., Sharma N., et al. Nasobiliary drainage in acute cholestatic hepatitis with pruritus. Dig Liver Dis 2009, 41(6):442-445.
21. Stapelbroek J.M., van Erpecum K.J., Klomp L.W., et al. Nasobiliary drainage induces long-lasting remission in benign recurrent intrahepatic cholestasis. Hepatology 2006, 43(1):51-53.
22. Toros A.B., Ozerdenen F., Bektas H., et al. A case report: nasobiliary drainage inducing remission in benign recurrent intrahepatic cholestasis. Turk J Gastroenterol 2012, 23(1):75-78.
23. Eisendle K., Muller H., Ortner E., et al. Pruritus of unknown origin and elevated total serum bile acid levels in patients without clinically apparent liver disease. J Gastroenterol Hepatol 2011, 26(4):716-721.
24. Jones D.E. Pathogenesis of cholestatic itch: old questions, new answers, and future opportunities. Hepatology 2012, 56(4):1194-1196.
25. Hashimoto T., Ohata H., Momose K. Itch-scratch responses induced by lysophosphatidic acid in mice. Pharmacology 2004, 72(1):51-56.
26. Reyes H., Ribalta J., Gonzalez-Ceron M. Idiopathic cholestasis of pregnancy in a large kindred. Gut 1976, 17(9):709-713.
27. Holzbach R.T., Sivak D.A., Braun W.E. Familial recurrent intrahepatic cholestasis of pregnancy: a genetic study providing evidence for transmission of a sex-limited, dominant trait. Gastroenterology 1983, 85(1):175-179.
28. Hirvioja M.L., Kivinen S. Inheritance of intrahepatic cholestasis of pregnancy in one kindred. Clin Genet 1993, 43(6):315-317.
29. Eloranta M.L., Heinonen S., Mononen T., et al. Risk of obstetric cholestasis in sisters of index patients. Clin Genet 2001, 60(1):42-45.
30. Pauli-Magnus C., Lang T., Meier Y., et al. Sequence analysis of bile salt export pump (ABCB11) and multidrug resistance p-glycoprotein 3 (ABCB4, MDR3) in patients with intrahepatic cholestasis of pregnancy. Pharmacogenetics 2004, 14(2):91-102.
31. Mullenbach R., Bennett A., Tetlow N., et al. ATP8B1 mutations in British cases with intrahepatic cholestasis of pregnancy. Gut 2005, 54(6):829-834.
32. Pusl T., Beuers U. Intrahepatic cholestasis of pregnancy. Orphanet J Rare Dis 2007, 2:26.
33. Geenes V.L., Lim Y.H., Bowman N., et al. A placental phenotype for intrahepatic cholestasis of pregnancy. Placenta 2011, 32(12):1026-1032.
34. Leckie P., Tritto G., Mookerjee R., et al. 'Out-patient' albumin dialysis for cholestatic patients with intractable pruritus. Aliment Pharmacol Ther 2012, 35(6):696-704.
35. Pares A., Herrera M., Aviles J., et al. Treatment of resistant pruritus from cholestasis with albumin dialysis: combined analysis of patients from three centers. J Hepatol 2010, 53(2):307-312.
36. Gay M., Pares A., Carrascal M., et al. Proteomic analysis of polypeptides captured from blood during extracorporeal albumin dialysis in patients with cholestasis and resistant pruritus. PLoS One 2011, 6(7):e21850.
37. Schaefer B., Schaefer F., Wittmer D., et al. Molecular Adsorbents Recirculating System dialysis in children with cholestatic pruritus. Pediatr Nephrol 2012, 27(5):829-834.
38. Bellmann R., Graziadei I.W., Feistritzer C., et al. Treatment of refractory cholestatic pruritus after liver transplantation with albumin dialysis. Liver Transpl 2004, 10(1):107-114.
39. Pares A., Cisneros L., Salmeron J.M., et al. Extracorporeal albumin dialysis: a procedure for prolonged relief of intractable pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol 2004, 99(6):1105-1110.
40. Huster D., Schubert C., Achenbach H., et al. Successful clinical application of extracorporal albumin dialysis in a patient with benign recurrent intrahepatic cholestasis (BRIC). Z Gastroenterol 2001, 39(Suppl 2):13-14.
41. Gilchrest B.A., Rowe J.W., Brown R.S., et al. Ultraviolet phototherapy of uremic pruritus. Long-term results and possible mechanism of action. Ann Intern Med 1979, 91(1):17-21.
42. Decock S., Roelandts R., Steenbergen W.V., et al. Cholestasis-induced pruritus treated with ultraviolet B phototherapy: an observational case series study. J Hepatol 2012, 57(3):637-641.
43. Ko M.J., Yang J.Y., Wu H.Y., et al. Narrowband ultraviolet B phototherapy for patients with refractory uraemic pruritus: a randomized controlled trial. Br J Dermatol 2011, 165(3):633-639.
44. Bergasa N.V., Link M.J., Keogh M., et al. Pilot study of bright-light therapy reflected toward the eyes for the pruritus of chronic liver disease. Am J Gastroenterol 2001, 96(5):1563-1570.
45. Schmelz M., Schmidt R., Bickel A., et al. Specific C-receptors for itch in human skin. J Neurosci 1997, 17(20):8003-8008.
46. Ross S.E., Mardinly A.R., McCord A.E., et al. Loss of inhibitory interneurons in the dorsal spinal cord and elevated itch in Bhlhb5 mutant mice. Neuron 2010, 65(6):886-898.
47. Wolfhagen F.H., Sternieri E., Hop W.C., et al. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterology 1997, 113(4):1264-1269.
48. Terg R., Coronel E., Sorda J., et al. Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J Hepatol 2002, 37(6):717-722.
49. Wu Z., Kong M., Wang N., et al. Intravenous butorphanol administration reduces intrathecal morphine-induced pruritus after cesarean delivery: a randomized, double-blind, placebo-controlled study. J Anesth 2012, 26(5):752-757.
50. Reich A., Szepietowski J.C. Non-analgesic effects of opioids: peripheral opioid receptors as promising targets for future anti-pruritic therapies. Curr Pharm Des 2012, [Epub ahead of print].
51. Angst M.S., Lazzeroni L.C., Phillips N.G., et al. Aversive and reinforcing opioid effects: a pharmacogenomic twin study. Anesthesiology 2012, 117(1):22-37.
52. Bergasa N.V., Alling D.W., Vergalla J., et al. Cholestasis in the male rat is associated with naloxone-reversible antinociception. J Hepatol 1994, 20(1):85-90.
53. Thornton J.R., Losowsky M.S. Methionine enkephalin is increased in plasma in acute liver disease and is present in bile and urine. J Hepatol 1989, 8(1):53-59.
54. Nelson L., Vergnolle N., D'Mello C., et al. Endogenous opioid-mediated antinociception in cholestatic mice is peripherally, not centrally, mediated. J Hepatol 2006, 44(6):1141-1149.
55. Spivey J.R., Jorgensen R.A., Gores G.J., et al. Methionine-enkephalin concentrations correlate with stage of disease but not pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol 1994, 89(11):2028-2032.
56. Tandon P., Rowe B.H., Vandermeer B., et al. The efficacy and safety of bile acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus. Am J Gastroenterol 2007, 102(7):1528-1536.
57. Jones E.A., Neuberger J., Bergasa N.V. Opiate antagonist therapy for the pruritus of cholestasis: the avoidance of opioid withdrawal-like reactions. QJM 2002, 95(8):547-552.
58. Mayo M.J., Handem I., Saldana S., et al. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology 2007, 45(3):666-674.
59. Muller C., Pongratz S., Pidlich J., et al. Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial. Eur J Gastroenterol Hepatol 1998, 10(10):865-870.
60. Hasanein P. The endocannabinoid transport inhibitor AM404 modulates nociception in cholestasis. Neurosci Lett 2009, 462(3):230-234.
61. Cichewicz D.L., Martin Z.L., Smith F.L., et al. Enhancement mu opioid antinociception by oral delta9-tetrahydrocannabinol: dose-response analysis and receptor identification. J Pharmacol Exp Ther 1999, 289(2):859-867.
62. Inoue M., Rashid M.H., Fujita R., et al. Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling. Nat Med 2004, 10(7):712-718.
63. Lin M.E., Rivera R.R., Chun J. Targeted deletion of LPA5 identifies novel roles for lysophosphatidic acid signaling in development of neuropathic pain. J Biol Chem 2012, 287(21):17608-17617.
64. Nieto-Posadas A., Picazo-Juarez G., Llorente I., et al. Lysophosphatidic acid directly activates TRPV1 through a C-terminal binding site. Nat Chem Biol 2012, 8(1):78-85.
65. Van Mil S.W., Milona A., Dixon P.H., et al. Functional variants of the central bile acid sensor FXR identified in intrahepatic cholestasis of pregnancy. Gastroenterology 2007, 133(2):507-516.
66. Lucey M.R., Neuberger J.M., Williams R. Primary biliary cirrhosis in men. Gut 1986, 27(11):1373-1376.
67. Chapman R., Fevery J., Kalloo A., et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010, 51(2):660-678.
68. Kremer A.E., Maillette de Buy W.L., Oude Elferink R.P., et al. Ned Tijdschr Geneeskd 2011, 155(52):A4045. [in Dutch].
69. Kunzmann S., Kullak-Ublick G.A., Greiner A., et al. Effective opiate-receptor antagonist therapy of cholestatic pruritus induced by an oral contraceptive. J Pediatr Gastroenterol Nutr 2005, 40(5):596-599.
70. Glantz A., Reilly S.J., Benthin L., et al. Intrahepatic cholestasis of pregnancy: amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. Hepatology 2008, 47(2):544-551.
71. Takeo C., Ikeda K., Horie-Inoue K., et al. Identification of Igf2, Igfbp2 and Enpp2 as estrogen-responsive genes in rat hippocampus. Endocr J 2009, 56(1):113-120.
72. Sun L.S. Gender differences in pain sensitivity and responses to analgesia. J Gend Specif Med 1998, 1(1):28-30.
73. Lawson K.P., Nag S., Thompson A.D., et al. Sex-specificity and estrogen-dependence of kappa opioid receptor-mediated antinociception and antihyperalgesia. Pain 2010, 151(3):806-815.
74. Green A.D., Young K.K., Lehto S.G., et al. Influence of genotype, dose and sex on pruritogen-induced scratching behavior in the mouse. Pain 2006, 124(1-2):50-58.
75. Kremer A.E., Beuers U., Oude-Elferink R.P., et al. Pathogenesis and treatment of pruritus in cholestasis. Drugs 2008, 68(15):2163-2182.
76. Chen S.C., Liu B.C., Chen C.W., et al. Intradermal pregnenolone sulfate attenuates capsaicin-induced nociception in rats. Biochem Biophys Res Commun 2006, 349(2):626-633.
77. Kirby J., Heaton K.W., Burton J.L. Pruritic effect of bile salts. Br Med J 1974, 4(5946):693-695.
78. Di P.C., Tritapepe R., Rovagnati P., et al. Double-blind placebo-controlled clinical trial of microporous cholestyramine in the treatment of intra- and extra-hepatic cholestasis: relationship between itching and serum bile acids. Methods Find Exp Clin Pharmacol 1984, 6(12):773-776.
79. Ghent C.N., Bloomer J.R. Itch in liver disease: facts and speculations. Yale J Biol Med 1979, 52(1):77-82.
80. Geenes V., Williamson C. Intrahepatic cholestasis of pregnancy. World J Gastroenterol 2009, 15(17):2049-2066.
81. Hohenester S., Oude-Elferink R.P., Beuers U. Primary biliary cirrhosis. Semin Immunopathol 2009, 31(3):283-307.
82. Pascual M.J., Serrano M.A., El-Mir M.Y., et al. Relationship between asymptomatic hypercholanaemia of pregnancy and progesterone metabolism. Clin Sci (Lond) 2002, 102(5):587-593.
83. Ghent C.N., Carruthers S.G. Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. Gastroenterology 1988, 94(2):488-493.